Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
← catalyst calendarNCT07227415 · readout in 440 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
224estimated
Sites
128
Countries
Australia, China, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-10 | actual | When the study began enrolling |
| Primary completion | 2027-11-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Renal Cell
- Advanced Renal Cell Carcinoma
- Renal Cancer
- Renal Neoplasm
- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Clear-cell Metastatic Renal Cell Carcinoma
- Carcinoma, Renal Cell Metastasis
- Advanced or Metastatic Renal Cell Carcinoma
- Carcinoma, Renal Cell, Advanced
- Metastatic Renal Cell Cancer
- Metastatic Renal Cell Carcinoma ( mRCC)
- Metastatic/Advanced Renal Cell Carcinoma
Interventions
- Drug: PF-08634404 — also filed as SSGJ-707
- Drug: Ipilimumab — also filed as yervoy
- Drug: Axitinib
Primary outcomes
what the primary-completion date above is the date OFConfirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigator
measured Up to approximately 3 years
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Through 90 days after the last study intervention (Up to approximately 3 years)
Number of participants with dose limiting toxicity (DLT)
measured Though end of DLT evaluation period (Up to approximately 3 years)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed